X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, Viatris divests its rights to women's healthcare products Duphaston (dydrogesterone) and Femoston (estradiol/dydrogesterone) to Theramex.
Lead Product(s): Dydrogesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Duphaston
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Viatris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment October 10, 2023
Details:
Through the agreement, Viatris divests its rights to women's healthcare products Duphaston (dydrogesterone) and Femoston (sstradiol/dydrogesterone) to Theramex and its Women's Healthcare business, primarily related to oral and injectable contraceptives, to Insud Pharma.
Lead Product(s): Dydrogesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Duphaston
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Viatris
Deal Size: $3,370.0 million Upfront Cash: Undisclosed
Deal Type: Divestment October 01, 2023
Details:
Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , Australia and Brazil.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Eladynos
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Radius Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2023
Details:
Yselty (Linzagolix) is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
Lead Product(s): Linzagolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Yselty
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: ObsEva
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
Details:
Femarelle® is a non-hormonal food supplement developed to help women manage symptoms in perimenopause, products cover all menopause stages to improve symptoms and women's bone health and will be available in different countries.
Lead Product(s): Tofu Extract,Flaxeed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Femarelle
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
ObsEva has entered into a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in Europe. Theramex’s extensive women’s health commercial infrastructure includes a dedicated sales force of more than 180 representatives.
Lead Product(s): Linzagolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: OBE-2109
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: ObsEva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 25, 2022
Details:
Intrarosa is now available in this market as the first and only locally acting DHEA (dehydroepiandrosterone) treatment indicated for postmenopausal women experiencing moderate to severe symptoms associated with vulvovaginal atrophy (VVA).
Lead Product(s): Prasterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Intrarosa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endoceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 14, 2022
Details:
Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids. Linzagolix is also in development as a potential treatment for endometriosis-associated pain. Linzagolix is not currently approved for any indication anywhere in the world.
Lead Product(s): Linzagolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ObsEva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 10, 2022
Details:
Theramex has entered into an agreement with Enzene Biosciences to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors.
Lead Product(s): Tocilizumab,Methotrexate
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Enzene Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 23, 2021
Details:
The real world PRO-E2 safety study confirmed that the risk of venous thromboembolism is at least as low with Zoely (NOMAC-E2) as with levonorgestrel-containing combined oral contraceptives. NOMAC-E2 is only monophasic contraceptive pill using body-identical 17B-estradiol.
Lead Product(s): Nomegestrol Acetate,Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Zoely
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
